Search results

Found 16 pages
AUTHOR: Neil Canavan

5 Dec 2014:

Agios early-stage AML drug shines

Agios Pharmaceuticals’ AG-120, a first-in-class inhibitor of the IDH1 mutant protein has shown remarkable efficacy in an early-stage trial in patients with acute myeloid leukaemia. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/agios_early-stage_aml_drug_shines_1002868

11 Dec 2014:

Haematologists love their CARs

There’s nothing like getting a new CAR, in fact, it just might save your life. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/haematologists_love_their_cars_1002898

2 Oct 2014:

Oncologists hail the beauty of CLEOPATRA

Research oncologists are not given to hyperbole, so when the words, “extraordinary” and “unprecedented” are used during a scientific presentation you need to pay attention. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/oncologists_hail_the_beauty_of_cleopatra_1002565

5 Jun 2014:

Nanobiotix heavy metal treatment rocks ASCO

It is hard to deny the power of heavy metal – not so much Metallica but X-ray-enhancing nanoparticles made of hafnium. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/nanobiotix_heavy_metal_treatment_rocks_asco_1002021

9 Oct 2014:

High hopes for Helsinn's cancer cachexia drug

A novel compound developed to prevent the ravages of cancer-induced anorexia-cachexia (CACS) has for the first time demonstrated a significant improvement in lean body mass in patients with advanced cases of non-small cell lung cancer. - News -

by Neil Canavan

https://www.pharmatimes.com/news/high_hopes_for_helsinns_cancer_cachexia_drug_1002604

2 Oct 2014:

Practice-changing treatment for melanoma

Once again, a drug that enhances a patient’s own immune system has shown a marked improvement in tumour regression as compared to standard chemotherapy regimens in the treatment of advanced melanoma. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/practice-changing_treatment_for_melanoma_1002566

27 Nov 2014:

Impressive survival data for Clovis' rociletinib

Interim results for rociletinib, Clovis Oncology’s third-generation tyrosine kinase inhibitor have shown impressive activity in lung cancer patients with the T790M mutation – a patient population with few treatment options. - News - P

by Neil Canavan

https://www.pharmatimes.com/news/impressive_survival_data_for_clovis_rociletinib_1002832

3 Jun 2014:

B-MS immunotherapy combo hits the mark in melanoma

The combined use of two new agents that boost the immune system has demonstrated an unprecedented improvement in tumour regression and overall survival for patients with advanced melanoma. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/b-ms_immunotherapy_combo_hits_the_mark_in_melanoma_1002010

1 Jun 2014:

Zeltia drug may offer sea change in ovarian cancer

Lurbinectedin, a drug developed by Zeltia unit PharmaMar and mined from the ocean’s depths, has improved survival for patients with advanced ovarian cancer, adding months of life in this hard-to-treat patient population. - News - PharmaTimes

by Neil Canavan

https://www.pharmatimes.com/news/zeltia_drug_may_offer_sea_change_in_ovarian_cancer_1002003

2 Jun 2014:

Pharmacyclics/J&J's ibrutinib could revolutionise CLL

Pharmacyclics and Johnson & Johnson’s ibrutinib has caused a stir at the American Society of Clinical Oncology meeting in Chicago, with many observers predicting that it will revolutionise treatment of chronic lymphocytic leukaemia. - News -

by Neil Canavan

https://www.pharmatimes.com/news/pharmacyclicsj_and_js_ibrutinib_could_revolutionise_cll_1002008